Vesicular Stomatitis Virus (VSV)

Dear Colleagues,

Vesicular stomatitis virus (VSV) is a vector-borne rhabdovirus affecting horses, cattle, swine, small ruminants, lamas, and alpacas, among other species. In cattle and pigs, the disease resembles foot and mouth disease, a devastating transboundary animal disease. Humans can become infected when handling affected animals, or in laboratory exposures, causing non-lethal flu-like illness. Incursions of VSV into the US from endemic regions in Southern Mexico occur sporadically at 5–10-year intervals. However, the epidemiology and environmental factors mediating incursion and transmission remain poorly understood. In addition to being a pathogen of agricultural concern, VSV is the prototype single-stranded negative-sense RNA virus used to understand molecular virology, virus evolution, viral transcription and replication, innate immune evasion, and adaptive immune response to viral infections. This knowledge has come from classical virology and from reverse genetics. VSV was among the first negative-strand RNA viruses to have a reverse genetic system, which led to the development of VSV as a vaccine vector, in immune therapy, and as an oncolytic virus vector used in human clinical trials.

In this Special Issue, we will explore novel insights into VSV and address long-standing unanswered questions about disease ecology, pathogenesis, and how VSV became a tool to fight infectious diseases and cancer. Topics covered will include the following: pathogenesis, innate immune evasion, virus–vector interactions, virus–host interactions, epidemiology, entry, assembly, replication, transcription, vaccine platforms, and vectored oncolytics.

Dr. Chad Mire
Dr. Luis L. Rodriguez
Dr. Andrea Marzi
Prof. Dr. Michael A. Whitt
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• pathogenesis
• innate immune evasion
• Virus–vector interactions
• Virus–host interactions
• epidemiology
• entry
• assembly
• replication
• transcription
• vaccine
• oncolytic